Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Dermipsor Reports Positive Phase 2b Results Showing Efficacy and Synergy of its Leading Product DPS-101, a Non- Steroidal Combination Drug to Treat Psoriasis the data showed statistical significant efficacy in most arms.
November 21st, 2008
The data showed statistical significant efficacy in most arms. Based on these results the company expects to initiate a pivotal Phase 3 study in 2009 Dermipsor Ltd, a leading clinical-stage drug development company focusing on novel therapies for the dermatology market, reports detailed analysis of the Phase 2b clinical trial results for its lead product DPS-101 in psoriasis patients. DPS-101 is a novel topical non-steroidal combination of 2 active ingredients – calcipotriol and nicotinamide – for the treatment of plaque psoriasis. The Phase 2b dose-ranging study was a randomized, double-blind, placebo-controlled, 12 week, 7 arm...
Source: Health Business Week (2008-11-21)
|
